Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Lipocine Inc (LPCN)

Lipocine Inc (LPCN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154 PR Newswire - Thu Jun 4, 7:00AM CDT

Live webinar to take place on Friday, June 12, 2026 at 11:00 AM Eastern Time

LPCN : 2.46 (-3.91%)
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting PR Newswire - Tue May 19, 7:00AM CDT

SALT LAKE CITY , May 19, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral...

LPCN : 2.46 (-3.91%)
Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase PR Newswire - Mon May 18, 7:00AM CDT

SALT LAKE CITY , May 18, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral...

LPCN : 2.46 (-3.91%)
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 PR Newswire - Thu May 7, 3:05PM CDT

SALT LAKE CITY , May 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral...

LPCN : 2.46 (-3.91%)
Lipocine: Q1 Earnings Snapshot AP - Thu May 7, 1:11PM CDT

Lipocine: Q1 Earnings Snapshot

LPCN : 2.46 (-3.91%)
Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression PR Newswire - Thu Apr 2, 7:00AM CDT

SALT LAKE CITY , April 2, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective...

LPCN : 2.46 (-3.91%)
Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 PR Newswire - Tue Mar 10, 7:00AM CDT

SALT LAKE CITY , March 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective...

LPCN : 2.46 (-3.91%)
Lipocine: Q4 Earnings Snapshot AP - Tue Mar 10, 5:25AM CDT

Lipocine: Q4 Earnings Snapshot

LPCN : 2.46 (-3.91%)
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) PR Newswire - Wed Feb 18, 7:00AM CST

SALT LAKE CITY , Feb. 18, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective...

LPCN : 2.46 (-3.91%)
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) PR Newswire - Tue Jan 20, 7:00AM CST

SALT LAKE CITY , Jan. 20, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective...

LPCN : 2.46 (-3.91%)

Barchart Exclusives

This Wannabe Dividend King Had a Tough H1. Expect Some Relief in H2. Barchart - Wed Jul 1, 6:30PM CDT
The dividend yield of MCD stock has risen to nearly 2.8%, with McDonald's on the verge of becoming a Dividend King. While not a tempting buy, dividend investors can start accumulating shares at these levels. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.